Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics.

ABSTRACT: Helicobacter pylori (H. pylori) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with H. pylori develop gastric cancer, Gastric cancer causes more than 750,000 deaths worldwide, with 90% of cases being caused by H. pylori. The eradication of this bacterium rests on multiple drug regimens as guided by various consensus. However, the efficacy of empirical therapy is decreasing due to antimicrobial resistance. In addition, biofilm formation complicates eradication. As the search for new antibiotics lags behind the bacterium's ability to mutate, studies have been directed toward finding new anti-H. pylori agen

SUBMITTER: Savitri CMA 

PROVIDER: S-EPMC11509656 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature